PepCalcs
    Back to Library

    VIP

    Phase 3 TrialsActive clinical research (sarcoidosis, pulmonary hypertension, IBD, autoimmune disease). Not FDA approved as a therapeutic.

    Vasoactive Intestinal Peptide

    Description

    A vasoactive peptide with broad physiological effects including vasodilation, immune modulation, and neuroprotection.

    Dose:50 mcg
    Frequency:Daily (8 weeks on/off cycle)
    Administration Method: IN
    CategoryImmunity
    Half-LifeApproximately 1-2 minutes in plasma due to rapid peptidase degradation.

    Overview

    Vasoactive Intestinal Peptide (VIP) is an endogenous neuropeptide with broad effects on the cardiovascular, GI, immune, and nervous systems. It promotes vasodilation, downregulates Th1/Th17 inflammatory responses, and supports neuroprotection. Clinical and preclinical studies have explored VIP for autoimmune encephalomyelitis, colitis, pulmonary hypertension, and sarcoidosis.

    Mechanism of Action

    28-amino-acid neuropeptide of the secretin/glucagon family; binds VPAC1 and VPAC2 G-protein-coupled receptors, raising cAMP. Produces vasodilation, smooth muscle relaxation, immune modulation, and anti-inflammatory effects.

    Benefits

    • •Vasodilation
    • •Immune modulation
    • •Neuroprotection
    • •Anti-inflammatory
    • •Sleep regulation
    • •Circadian rhythm

    Reported Side Effects

    • •Hypotension
    • •Flushing
    • •Tachycardia
    • •Headache
    • •Injection site reactions

    Safety Notes

    Rapid degradation limits practical dosing. Hypotensive effects require monitoring. Research use only.

    Scientific References

    PubChem (NIH)Wikipedia

    Related Immunity Peptides

    KPV

    KPV Tripeptide

    An anti-inflammatory tripeptide derived from alpha-MSH. Potent immunomodulatory properties help reduce inflammation and support gut health.

    500 mcg